Exelixis Q2 2022 Earnings Report
Key Takeaways
Exelixis announced its second quarter 2022 financial results with total revenues of $419.4 million and GAAP diluted EPS of $0.22. The company highlighted the 22 percent growth in cabozantinib franchise net product revenues year-over-year and key cabozantinib milestones.
Total revenues for the quarter ended June 30, 2022 were $419.4 million.
GAAP net income for the quarter ended June 30, 2022 was $70.7 million, or $0.22 per share, basic and diluted.
Non-GAAP net income for the quarter ended June 30, 2022 was $89.7 million, or $0.28 per share, basic and diluted.
Cash, cash equivalents, restricted cash equivalents and investments were $2.0 billion at June 30, 2022.
Exelixis
Exelixis
Exelixis Revenue by Segment
Forward Guidance
Exelixis is maintaining the following previously provided financial guidance for fiscal year 2022:
Positive Outlook
- Total revenues $1.525 billion - $1.625 billion
- Net product revenues $1.325 billion - $1.425 billion
- Cost of goods sold 5% - 6% of net product revenues
- Research and development expenses $725 million - $775 million
- Selling, general and administrative expenses $400 million - $450 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income